Speakers

Expand/Collapse

Ram Miller
Director Translational Medicine
Novartis

Day One

Wednesday, May 25th

4:00 pm | Considerations for Novel ALS Clinical Trials

Amir Lahav
Head of Digital R&D, Digital Healthcare Innovation
Mitsubishi Tanabe Pharma Holdings America

Day One

Wednesday, May 25th

9:00 am | Implementing Remote Monitoring Technology for Tracking ALS Outside the Clinic Using Wearable Sensors & Smartphone Apps

Andrew Wolff
Senior Vice President, Senior Fellow, Clinical Research & Development
Cytokinetics

Day One

Wednesday, May 25th

2:00 pm | Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS

Angela Genge
Chief Medical Officer
QurAlis

Day One

Wednesday, May 25th

2:00 pm | Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS

11:00 am | Exploring Electrophysiological Biomarkers of Diagnosis & Outcome in ALS

Dimitry Ofengeim
Head of Precision Neurology & Neuroinflammation Cluster
Sanofi

Day Two

Thursday, May 26th

1:30 pm | Investigating Pathways for Intervention: Targeting RIPK1 in ALS

11:00 am | Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies

Ferenc Tracik
Chief Medical Officer
NeuroSense Therapeutics

Day Two

Thursday, May 26th

9:00 am | From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS

James Berry
Chief, Division of ALS & Motor Neuron Diseases
Massachusetts General Hospital

Day One

Wednesday, May 25th

1:30 pm | Moving Beyond ALSFRS-R & Survival Endpoints: Exploring Patient Reported & Non-Traditional Outcome Measures

Jeremy Shefner
Professor & Chair of Neurology
Barrow Neurological Institute

Day One

Wednesday, May 25th

12:00 pm | Innovation in ALS Trial Design & Clinical Outcome Measures

Johanne Kaplan
Chief Development Officer
ProMIS Neurosciences

Day Two

Thursday, May 26th

11:00 am | Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies

Kasper Roet
Founder & Chief Executive Officer
QurAlis

Day Two

Thursday, May 26th

8:30 am | Harnessing New Insights into Human Genetics & Stem Cell Technology to Provide Genetically-Validated Targets for the Sporadic ALS Patient Populations

Leonard van den Berg
Professor of Neurology
University Medical Center Utrecht

Day One

Wednesday, May 25th

4:30 pm | TRICALS & the ENCALS Prediction Model: Innovating Clinical Trials in ALS

Mansuo Hayashi
Chief Scientific Officer
Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly

Sabrina Paganoni
Co-Director
Neurological Clinical Research Institute Massachusetts General Hospital

Day One

Wednesday, May 25th

2:30 pm | Driving Experimental Trial Design in ALS to Evaluate Multiple Interventions

Michael Benatar
Professor of Neurology
University of Miami

Day Two

Thursday, May 26th

11:30 am | Characterizing Pre-symptomatic ALS to Identify Opportunities for Early Therapeutic Intervention

Miroslaw Brys
Senior Director, Neurodegeneration Clinical Head
Eli Lilly & Company

Day Two

Thursday, May 26th

12:00 pm | SARM1 Inhibition as a Potential Therapeutic Strategy in ALS

Neil Cashman
Chief Scientific Officer & Co-founder
ProMIS Neurosciences

Day Two

Thursday, May 26th

4:30 pm | Chair’s closing remarks

2:00 pm | Generating Effective Therapeutic Strategies for Sporadic Disease with Gene Therapies in ALS

8:25 am | Chair’s Opening Remarks

Olivier Hermine
Chief Scientific Officer
AB Science

Day Two

Thursday, May 26th

3:30 pm | Exploring Mastocytosis & Kinases as the Basis of the History of Masitinib in ALS Mechanism of Action & Reviewing Clinical Results

11:00 am | Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies

Peter Vanderklish
Chief Scientific Officer
Spinogenix

Day Two

Thursday, May 26th

4:00 pm | Developing a Synaptic Regenerative Therapy in ALS Using a Novel Spinogenic Small Molecule

Ralph Kern
President & Chief Medical Officer
Brainstorm Cell Therapeutics

Day One

Wednesday, May 25th

5:00 pm | Chair’s Closing Remarks

9:30 am | Advancing Novel CSF Biomarkers to Evaluate ALS Target Engagement & Improve Therapeutic Outcomes

8:25 am | Chair’s Opening Remarks

Robert Bowser
Chief Scientific Officer, Professor & Chair of Translational Neuroscience
Barrow Neurological Institute

Day One

Wednesday, May 25th

2:00 pm | Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS

11:30 am | Validating Biomarkers & Use in Clinical Trials to Demonstrate Target Engagement & Eligibility Criteria for Enrollment

Robert Scannevin
Chief Scientific Officer
Verge Genomics

Day Two

Thursday, May 26th

9:30 am | Revolutionizing Discovery & Development of ALS Therapeutics Using Transformational, AI-Powered ‘All-in-Human’ Platforms

Stacy Rudnicki
Vice President, Clinical Research
Cytokinetics

Day One

Wednesday, May 25th

3:30 pm | Rethinking Inclusion & Exclusion Criteria: Should we be Dissecting Patient Heterogeneity?

Stephanie Fradette
Senior Medical Director, Clinical Development
Biogen

Day One

Wednesday, May 25th

2:00 pm | Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS

8:30 am | Interrogating Neurofilament as a Marker of Disease Activity & Treatment Response

Thomas Holm Pedersen
Chief Executive Officer
NMD Pharma

Day Two

Thursday, May 26th

2:30 pm | Stratifying ALS Patients into Clinically Relevant Subpopulations to Develop Targeted Therapeutics

11:00 am | Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies

Kelley Erb
Director, Digital & Quantitative Medicine
Biogen